Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Todd group part of Global Platform for the Prevention of Autoimmune Diabetes

As part of an international collaboration, the DIL group will identify infants with a significant genetic risk for type 1 diabetes to begin recruiting for POInT, a randomized controlled phase IIb trial to determine if daily administration of high-dose oral insulin in early life can prevent T1D-associated autoimmunity.

Read the full article

Categories